Department of Ophthalmology III, Quinze-Vingts National Ophthalmology Hospital, 28 rue de Charenton, 75012, Paris, France.
Quinze-Vingts National Ophthalmology Hospital, IHU FOReSIGHT, INSERM-DGOS CIC 1423, 17 rue Moreau, F-75012, Paris, France.
BMC Ophthalmol. 2021 Jul 10;21(1):273. doi: 10.1186/s12886-021-02032-z.
PreserFlo® MicroShunt (PM) (also known as InnFocus® MicroShunt) is a subconjunctival stent implanted ab externo via a minimally invasive surgical procedure. The current indication is progressive, mild to moderate, open angle glaucoma uncontrolled on topical medications. According to the literature, adverse events are rare, mild and transient.
Two cases of stand-alone PreserFlo MicroShunt® implantation in patients with uncontrolled open-angle glaucoma are reported. Exposure occurred 7 days and 3 months respectively after implantation. These cases shared common features including preexisting blepharitis and the lack of a Tenon's flap. In both cases, removal of the device was required after several attempts at repair.
PreserFlo MicroShunt® exposure is a potentially vision-threatening complication because of the risk of endophthalmitis. Potential risk factors include the absence of a Tenon's flap and pre-existing ocular surface inflammation. Ocular surface inflammation should be detected and treated prior to PM implantation. If a deficiency in Tenon's capsule is noted intraoperatively, close monitoring should be performed because of the higher risk of PM exposure.
PreserFlo® MicroShunt（PM）（也称为 InnFocus® MicroShunt）是一种通过微创外科手术植入巩膜下的支架。目前的适应证是对局部药物治疗无法控制的进展性、轻度至中度、开角型青光眼。根据文献报道，不良反应罕见、轻微且短暂。
报告了两例单独使用 PreserFlo MicroShunt®植入治疗未控制的开角型青光眼的病例。植入后分别发生在 7 天和 3 个月时出现暴露。这两个病例具有共同的特征，包括存在先前的睑缘炎和缺乏 Tenon 氏囊瓣。在这两个病例中，在多次尝试修复后都需要取出该装置。
PreserFlo MicroShunt®暴露是一种潜在的威胁视力的并发症，因为存在眼内炎的风险。潜在的危险因素包括缺乏 Tenon 氏囊瓣和先前存在的眼表面炎症。在 PM 植入前应检测和治疗眼表面炎症。如果术中发现 Tenon 氏囊缺损，由于 PM 暴露的风险较高，应密切监测。
